Hoffmann-la Roche

This study tests a small implant in the eye that slowly releases medication for wet age-related macular degeneration (AMD). The implant is refilled every 36 weeks, which could mean fewer doctor visits for injections. About 250 people who have already responded to standard injecti…

This early-stage study tests whether combining two experimental drugs (mosunetuzumab or glofitamab) with other targeted agents (CC-220 and/or CC-99282) is safe and effective for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior…

This study tests a new gene therapy called SPK-8011QQ in adult men with severe or moderately severe hemophilia A. The main goal is to check if the treatment is safe and tolerable. Only 5 participants will be enrolled, and the study is currently recruiting.

This study tests a new medicine called NXT007 to see if it works better than the standard factor VIII treatment at preventing bleeding episodes in people with hemophilia A who do not have inhibitors. About 126 participants aged 12 and older with severe or moderate hemophilia A wi…

This study tests a drug called satralizumab in children aged 2 to 11 with a rare disease called NMOSD, which causes inflammation in the nerves and spinal cord. The goal is to see how the drug works in the body, whether it is safe, and if it can prevent relapses. Only 8 children w…

This study tests whether adding a new drug called inavolisib to standard hormone therapy and a CDK4/6 inhibitor can help people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+, HER2-). About 450 adults whose cancer has not been treated for advanced disease wil…

This study is testing several different treatment combinations for people with multiple myeloma, a type of blood cancer. The goal is to see if these treatments are safe and how well they work at shrinking tumors and helping people live longer. About 200 participants will be enrol…

This study is for people with advanced breast cancer that has stopped responding to standard treatments. It tests several different drug combinations to see which ones work best for different types of the disease. About 316 participants will be enrolled, and the goal is to contro…

This study tests an experimental drug called trontinemab in 800 people with early Alzheimer's (mild memory problems to mild dementia). The goal is to see if it can slow down worsening of symptoms over 72 weeks compared to a placebo. Participants will have regular memory tests, br…

This study tests a once-weekly injection called enicepatide for weight loss in 2000 adults with obesity or overweight who do not have diabetes. Participants must have a BMI of 30 or higher, or a BMI of 27 with a weight-related health issue like high blood pressure. The main goal …

This study is testing the drug ocrelizumab in 60 Chinese adults with relapsing or primary progressive multiple sclerosis (MS). The goal is to see how well it controls relapses and reduces immune cells linked to MS. Participants receive the drug by infusion, and researchers monito…

This study tests an experimental drug called prasinezumab in 900 people with early-stage Parkinson's disease who are already on stable levodopa therapy. The goal is to see if the drug can delay worsening of motor symptoms compared to a placebo. Participants receive the drug or pl…

This study tests a new drug called glofitamab against standard treatments for mantle cell lymphoma that has returned or stopped responding to therapy. About 182 adults will be randomly assigned to receive glofitamab alone or one of two standard drug combinations. The main goal is…

This study tests a new medicine called NXT007 in people with severe or moderate hemophilia A, a bleeding disorder. The goal is to see if it is safe and helps control bleeding. The trial includes adults, teens, and children, both with and without inhibitors that make standard trea…

This study tests a new medicine called RG6496 in people who carry the gene for Huntington's disease. The goal is to check if it is safe and how the body handles it. About 40 participants will receive either the drug or a placebo, with an option to continue treatment in an open-la…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and shrinks tumors. About 320 adults who have not had prior treatment…

This study tests an experimental drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check safety and how the drug moves through the body, not to cure the disease. Participants will receive the drug as a shot under the skin, and the stu…

This study tests a new medicine called sefaxersen for people with a kidney disease called IgA nephropathy that is getting worse despite standard care. The drug aims to reduce protein in the urine and slow down kidney damage. About 428 adults will receive either sefaxersen or a pl…

This study compares two versions of the multiple sclerosis (MS) drug ocrelizumab given as a shot under the skin. About 182 adults with relapsing or primary progressive MS will get one dose of either the test or the marketed version. The goal is to see if the test version works ju…

This early-stage study tests a new drug (RO7673396) in people with advanced solid tumors that have RAS mutations and haven't responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors when given alone or …

This study tests a drug called obinutuzumab in teens (12-17) and children (5-11) with active lupus nephritis, a kidney complication of lupus. The goal is to see if the drug can help control kidney inflammation and improve kidney function. Participants are randomly assigned to rec…

This study tests a new drug combination (inavolisib plus other treatments) in 60 people with untreated, early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if the combination is safe and can shrink or eliminate tumors before surgery.…

This study compares a continuous glucose monitor (CGM) to standard finger-prick testing in 270 adults with type 1 or type 2 diabetes who use insulin injections. The goal is to see if the CGM helps people spend more time with blood sugar in the target range of 70-180 mg/dL. Partic…

This study tests if a combination of two drugs (inavolisib plus enzalutamide) works better than standard treatments for men with a certain type of advanced prostate cancer that no longer responds to hormone therapy. About 100 men will take part. The goal is to see if the combo ca…

This study tests whether adding a new drug (RO7268489) to the standard MS treatment ocrelizumab can slow disability progression in adults with progressive multiple sclerosis. About 360 participants will receive either the new drug or a placebo, and researchers will track walking …

This early-stage study tests an experimental oral drug, RO7795081, in 30 healthy Chinese adults who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it, not to prove weight loss yet. Participants will receive either the drug o…

This study tests the long-term safety of a small, refillable implant placed in the eye to deliver medication for wet age-related macular degeneration, a leading cause of vision loss. About 1000 people who have already used the implant in earlier studies will be followed for sever…

This study tests whether a new targeted drug (divarasib) plus an immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not …

This study tracks 800 adults in China who have ALK-positive early-stage lung cancer and took alectinib pills after surgery to remove their tumor. The goal is to see how long they stay cancer-free in real-world settings. Alectinib is a targeted therapy that blocks cancer growth, b…

This study tests several targeted therapies (drugs that attack specific cancer cell features) in people with metastatic colorectal cancer that has spread. Participants receive treatment based on their tumor's unique biomarkers. The goal is to see if these personalized approaches …

This study looks at how well and how safe the drug glofitamab works for Chinese adults whose diffuse large B-cell lymphoma returned or didn't respond after one prior treatment. About 300 people will take part across multiple hospitals. Researchers will track how long patients liv…

This study tests a medicine called emicizumab, given as a shot, to prevent bleeding in people with Type 3 von Willebrand disease, a severe blood clotting disorder. About 75 people aged 1 month and older will take part. Some will get emicizumab, while others continue their usual c…

This study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can safely reduce symptoms and lead to remission at 12 and 52 weeks. Participants must have tried other t…

This study tests an experimental drug called Afimkibart (RO7790121) in 160 adults with moderate to severe rheumatoid arthritis who did not get better with or could not tolerate standard treatments like TNF or JAK inhibitors. Participants will receive either the drug or a placebo …

This study tests a new drug (RO7771950) combined with two standard treatments for people with advanced HER2-positive breast cancer that has spread or cannot be removed. The new drug is designed to reach the brain, which is important because this cancer often spreads there. About …

This study looks at whether adding risdiplam early can help infants under 2 with spinal muscular atrophy (SMA) who already had gene therapy. About 28 children with two copies of the SMN2 gene will receive risdiplam and be monitored for 72 weeks. The goal is to see if this combina…

This study tests a new gene therapy called SPK-10001 for people with Huntington's disease. It involves a one-time infusion into specific brain areas to see if it is safe and can help control symptoms. About 53 adults with early-stage Huntington's will take part. The goal is to sl…

This study tests two different doses of inavolisib (a targeted drug) plus fulvestrant (hormone therapy) in 80 people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+, HER2-). The goal is to see if a lower dose works as well with fewer side effects. Participants…

This study is testing several new combinations of immunotherapy drugs in people with advanced liver cancer that cannot be removed by surgery. The goal is to see if these combinations can shrink tumors and control the disease for as long as possible. About 518 adults with advanced…

This study tests a new drug called RO7790121 for people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. About 350 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goa…

This study tests whether adding a personalized cancer vaccine (autogene cevumeran) to an immunotherapy drug (nivolumab) can better prevent bladder cancer from coming back after surgery. About 362 people with high-risk muscle-invasive bladder cancer will take part. The approach ai…

This study tests a new medicine called NXT007 against an existing drug, emicizumab, to see which better prevents bleeding episodes in people with hemophilia A. The trial includes 360 participants aged 12 and older with severe or moderate hemophilia A, with or without inhibitors. …

This study tests a drug called satralizumab in people with two rare autoimmune diseases that cause brain inflammation (NMDAR and LGI1 encephalitis). The goal is to see if it improves disability and reduces the need for emergency treatments. About 152 adults will receive either th…

This study tests whether adding the drug inavolisib to standard maintenance therapy (Phesgo) can help keep advanced HER2-positive breast cancer with a specific gene mutation (PIK3CA) from getting worse. About 230 adults with this type of breast cancer will receive either the comb…

This study tests a new drug called glofitamab, given alone or with standard chemotherapy, in children and young adults (ages 6 months to under 30) whose mature B-cell non-Hodgkin lymphoma has returned or not responded to treatment. The goal is to see if the drug is safe and can s…

This study tests several different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. The goal is to see which combinations work best to shrink tumors or slow the disease. About 792 adults with various breast cancer types wi…

This study tests a new drug called trontinemab in 800 people with early Alzheimer's (mild memory loss to mild dementia). The goal is to see if it can slow down the disease over 72 weeks. Participants will receive either the drug or a placebo, and neither they nor their doctors wi…

This study tests a combination of three drugs (glofitamab, gemcitabine, and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a special steroid plan can reduce a common side effect call…

This early-stage study is for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. Researchers are testing a drug called mosunetuzumab, either alone or combined with another drug (venetoclax), to see if they are safe and …

This study tests a new hormone therapy called giredestrant against an existing one (fulvestrant) for people with a common type of advanced breast cancer (ER+/HER2-) that has become resistant to prior hormone treatment. Both groups also receive a targeted therapy (CDK4/6 inhibitor…

This study tests a drug called alectinib in children and teens with ALK fusion-positive solid or central nervous system (CNS) tumors that have not responded to prior treatments or have no good standard options. The goal is to see if the drug is safe, how it works in the body, and…

This study looks at the long-term safety of astegolimab in people with chronic obstructive pulmonary disease (COPD). Participants must have already completed a one-year treatment period in a previous study. The main goal is to track any side effects over an extended time.

This study tests a small implant placed in the eye that releases medication every 24 weeks to treat diabetic macular edema, a leading cause of vision loss in people with diabetes. About 634 adults with the condition will receive either the implant or standard monthly eye injectio…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The cancer must have a specific gene change (PIK3CA mutation) and be hormone receptor-positive and HER2-negative. About …

This study looks at how the drug risdiplam works in newborn babies with spinal muscular atrophy (SMA), a serious muscle-weakening disease. Ten infants under 20 days old will receive the medicine to check its safety and how the body processes it. The goal is to find better ways to…

This study tests a new medicine called RO7790121 (Afimkibart) for people with moderate-to-severe Crohn's disease. About 600 adults who haven't responded well to other treatments will receive either the drug or a placebo. The goal is to see if the drug can reduce symptoms and heal…

This study tests whether adding the drug inavolisib to a standard two-drug combination (ribociclib and fulvestrant) can shrink tumors or slow disease progression in people with a specific type of advanced breast cancer (HR+/HER2- with chromosome 8p loss). About 80 participants wh…

This study tests an investigational drug called satralizumab to see if it can prevent relapses in people with MOGAD, a rare autoimmune disease that attacks the brain and spinal cord. About 152 participants aged 12 and older who have had recent attacks will receive either satraliz…

This study tests an experimental drug called fenebrutinib in 12 children and teens (ages 10 to under 18) with relapsing multiple sclerosis. The goal is to see how the drug works in the body, whether it reduces brain lesions, and if it is safe. Participants can choose to continue …

This early-stage study tests a new drug called RO7812653 in about 50 people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body handles it. Participants receive a single dose injected into the spine and are closely monitored for side eff…

This study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema). It is for those who already took the drug in an earlier study. About 120 adults will be followed to see how well the drug controls their eczema over time …

This study offers ongoing treatment with ocrelizumab to about 500 adults with multiple sclerosis who were in earlier Roche-sponsored trials and lack other access. Researchers will track how the drug affects physical function, safety, and daily life over time. The goal is to keep …

This early-stage study tests a new drug called glofitamab combined with two chemotherapy drugs (gemcitabine and oxaliplatin) in about 50 US adults with diffuse large B-cell lymphoma that has returned or stopped responding to prior treatment. The main goals are to check safety and…

This study tests an experimental drug called astegolimab in people with COPD who have frequent flare-ups. About 1,290 current or former smokers will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug reduces the number of moderate to severe COP…

This study will follow about 1,000 people in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will track vision changes, eye thickness, and treatment patterns over one year to see ho…

This early-stage study tests a drug called inavolisib, alone or with immunotherapy, in people whose cancers have a specific change in the PIK3CA gene. The goal is to see if these treatments are safe and can shrink tumors. About 30 adults with advanced head and neck cancer or othe…

This study is for children under 2 with spinal muscular atrophy (SMA) who received gene therapy but then stopped getting better or started to decline. Researchers want to see if adding a medicine called risdiplam can help them regain motor skills like sitting or crawling. The stu…

This study tests a new drug called RO7790121 (Afimkibart) in about 425 people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce symptoms and heal the gut lining compared to a placebo. Participants wil…

This study tests a new weekly injection called enicepatide to help people with obesity or overweight and type 2 diabetes lose weight. About 1,600 participants will receive either the drug or a placebo for 72 weeks. The main goal is to see how much weight they lose and if the drug…

This early-stage study tests a new treatment called CEA-PRIT 2.0 for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step process to deliver a radioactive particle directly to cancer cells, aiming to control the…

This early-stage trial tests a drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety and how the body processes it. Researchers will also watch for signs th…

This study has two main goals. First, it will check if the flu virus in children under 12 becomes resistant to the medicine baloxavir marboxil. Second, for a smaller group of families, it will track whether the flu spreads from the treated child to other people living in the same…

This study aims to create a blood test that helps doctors quickly diagnose traumatic brain injury (TBI) and predict how patients will recover. It will also test if the same blood test can spot complications in hospitalized patients. The study will enroll 2000 adults who come to t…

This study is for people with certain types of lung or liver cancer who are already receiving atezolizumab as part of their routine care. Researchers want to know how satisfied patients are with the subcutaneous (under the skin) injection and how it affects their quality of life.…

This early-stage study tests a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The main goal is to see if the drug is safe and tolerable when given as a shot or IV. Participants are not on other MS treatments during the study. This is not a cure; it aims to …

This early-stage study tests a new drug called RO7806881 in healthy volunteers to see if it is safe and how the body processes it. About 128 participants will receive either the drug or a placebo. The study does not aim to treat any disease, but to gather important safety informa…

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab in real-world clinics. Researchers will track vision changes, treatment schedules, and safety over two years. The goal is …

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This study watches 842 people with multiple sclerosis who are starting a new under-the-skin injection of ocrelizumab. Researchers will ask how satisfied patients are with the injection after 12 months and check nerve health markers. The goal is to understand real-world experience…

This study is a large pre-screening effort to identify people who may be eligible for future Alzheimer's drug trials. It will enroll up to 13,000 adults with recent memory concerns, measuring a key blood biomarker (pTau217) and cognitive performance. The goal is to efficiently ma…

This early-stage study tests an experimental drug called RO7795081 in 40 healthy overweight or obese adults. The main goals are to check if the drug is safe and how it interacts with common statins (pitavastatin and rosuvastatin). Participants will receive either the drug or a pl…

This study looks at 100 people with early-stage HER2-positive breast cancer in Serbia to see if traveling farther for treatment affects how well they stick to their medication plan. Researchers will compare those who have to travel more with those who don't. The goal is to unders…

This early-stage study is testing an experimental drug called RO7763505 to see if it is safe and how the body processes it. The trial involves about 196 participants, first in healthy volunteers and then in people with stable coronary artery disease. Researchers will monitor side…

This study is for people with Type 3 von Willebrand disease, a rare bleeding disorder. Researchers want to see how often bleeding happens and how it affects quality of life while participants receive their usual preventive treatment. About 40 people will be observed for at least …

This study is testing a new digital platform designed to help doctors and patients track multiple sclerosis (MS) over time. About 500 people with relapsing-remitting MS and their healthcare providers will use the platform for two years. The goal is to see if the tool is easy to u…

This study aims to understand specific genetic markers (called SNPs) in people who carry the Huntington disease gene. Researchers will collect a blood sample and medical history from 600 adults aged 25 to 60. No treatment is given; the goal is to learn more about the disease's ge…

This study is a registry that collects information from 15,000 adults with solid tumors who have had a genetic test (next-generation sequencing). The goal is to understand how genetic test results relate to treatments and patient outcomes over time. No new treatments are given; i…